GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Minsheng Healthcare Co Ltd (SZSE:301507) » Definitions » YoY EBITDA Growth

Hangzhou Minsheng Healthcare Co (SZSE:301507) YoY EBITDA Growth : -18.60% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Hangzhou Minsheng Healthcare Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hangzhou Minsheng Healthcare Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -18.60%.

Hangzhou Minsheng Healthcare Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.20.

Hangzhou Minsheng Healthcare Co YoY EBITDA Growth Historical Data

The historical data trend for Hangzhou Minsheng Healthcare Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Minsheng Healthcare Co YoY EBITDA Growth Chart

Hangzhou Minsheng Healthcare Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial - - - 8.02 -7.86

Hangzhou Minsheng Healthcare Co Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.85 112.16 -15.56 -35.00 -18.60

Hangzhou Minsheng Healthcare Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hangzhou Minsheng Healthcare Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.422-0.458)/ | 0.458 |
=-7.86 %

Hangzhou Minsheng Healthcare Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(0.197-0.242)/ | 0.242 |
=-18.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Minsheng Healthcare Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Hangzhou Minsheng Healthcare Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Minsheng Healthcare Co (SZSE:301507) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Minsheng Healthcare Co Ltd (SZSE:301507) » Definitions » YoY EBITDA Growth
Comparable Companies
SHSE:688176 SHSE:600713 SHSE:600666 SZSE:000411 SZSE:300109 SZSE:301096 SZSE:300006 SZSE:301281 SHSE:600613 SZSE:002198 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
N/A
Address
No. 101, Xintian Road, Donghu Street, Linping, Zhejiang, Hangzhou, CHN, 311100
Website
http://www.21vita.com
Hangzhou Minsheng Healthcare Co Ltd focuses on the field of vitamin and mineral supplements and is a high-tech enterprise integrating research and development, production and sales of vitamin and mineral over-the-counter drugs and health food. The company's current main product is 21 Golden Vita multi-dimensional element tablets (21).

Hangzhou Minsheng Healthcare Co (SZSE:301507) Headlines

No Headlines